ATATcH Alternating Treatment Plans for Advanced Head and Neck or Lung Cancer
This study is exploring a new way to give chemotherapy and immunotherapy for advanced head and neck or lung cancers. It tests alternating cycles of chemotherapy (Paclitaxel, Pemetrexed, 5Fluorouracil, Carboplatin) plus immunotherapy (Pembrolizumab) with immunotherapy alone. The goal is to see if giving chemotherapy less often (every six weeks instead of every three) can still effectively fight your cancer while improving your quality of life. The study is looking for about 150 adults, aged 18 and older, with stage IV non-small cell lung cancer or head and neck cancer. Researchers will measure how many patients complete their initial chemotherapy cycles to understand the treatment's success. The current status of this study is unclear.
- Study design
- This is a three-arm, parallel phase II study aiming to enroll about 150 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at up to 30 weeks, which suggests follow-up for at least that duration.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
ATATcH Alternating Treatment Plans for Advanced Cancer
At a glance
Conditions
Where it's being run
11 sites across 1 statesStudy leadership
- Missak Haigentz, MD · PRINCIPAL_INVESTIGATOR · Rutgers Cancer Institute of New Jersey
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Confidence Interval (CI) estimate of patients completing induction chemotherapy cyclesup to 30 weeks
The primary endpoint of this three-arm, parallel phase II study is the percentage of patients in each of the study arms receiving 1, 2, 3 and 4 (up to 6 cycles for head and neck cancer) induction combination chemoimmunotherapy (termed "A") cycles (reflecting timepoints of 0, six weeks, twelve weeks, and eighteen weeks on study, respectively \[up to 30 weeks for patients with head and neck cancer\]).